Significant Breakthrough in Lung Cancer Treatment
The HARMONi-A study marks an important advancement in the battle against EGFR-positive non-squamous non-small cell lung cancer (nsq-NSCLC). This trial stands out as the first Phase III study validating an immunotherapy approach using ivonescimab for patients who have developed resistance to EGFR-TKI treatments. The significant results have raised expectations for improved treatment strategies and patient outcomes.
Study Results Highlight Clinical Benefits
With a median follow-up period of 32.5 months, the findings from the HARMONi-A study demonstrated that the combination of ivonescimab and chemotherapy yielded a median overall survival (OS) of 16.8 months. In contrast, the control group, which received chemotherapy alone, had a median OS of only 14.1 months. The hazard ratio for OS was reported at 0.74, with a p-value of 0.019, signifying robust statistical significance.
Consistent Benefits Among Subgroups
Notably, the OS benefit provided by the ivonescimab combination was consistent across various patient demographics. Improved survival rates were observed regardless of factors such as the presence of brain metastases or specific EGFR mutation types. This consistency underscores the potential for ivonescimab to impact diverse populations of lung cancer patients positively.
Safety Profile Remains Favorable
Throughout the study, the ivonescimab combination therapy maintained an excellent safety profile. No new safety concerns arose during the follow-up period. The incidence of common treatment-related adverse events was comparable between the ivonescimab group and the control group, reinforcing the treatment's viability.
A History of Encouraging Results
The HARMONi-A study had previously met its primary endpoint, showcasing significant improvement in progression-free survival (PFS) at an interim analysis. With results from this final OS analysis, ivonescimab reinforces its value in enhancing both PFS and OS, positioning it as a notable option for patients facing treatment challenges with existing therapies.
Regulatory Approvals and Future Prospects
In May 2024, ivonescimab received approval for market launch in China, subsequently securing its place on the National Reimbursement Drug List in November of the same year. This development paves the way for improved access to this innovative treatment for patients in need.
Interestingly, Akeso's global partner, Summit Therapeutics, has announced plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). This submission, anticipated in late 2025, aims to secure approval for ivonescimab in combination with chemotherapy for treating EGFR-positive, TKI-resistant patients.
About Akeso
Akeso, Inc. (HKEX: 9926.HK) is a leading biopharmaceutical company dedicated to the development of innovative biological medicines. Since its establishment in 2012, Akeso has built a comprehensive integrated R&D innovation system, focusing on cancer therapies and other major diseases. The company's ambition includes offering affordable therapeutic options to patients worldwide, bolstered by a robust pipeline and advanced operational capabilities.
Frequently Asked Questions
What is the significance of the HARMONi-A study?
The HARMONi-A study is the first Phase III trial to demonstrate meaningful survival benefits for patients with EGFR-TKI-resistant NSCLC using ivonescimab.
How does ivonescimab compare to traditional chemotherapy?
Ivonescimab, when combined with chemotherapy, showed a median OS of 16.8 months, significantly outpacing the 14.1 months achieved with chemotherapy alone.
What are the safety results for the ivonescimab regimen?
The safety profile of the ivonescimab combination therapy was favorable, with no new safety signals and comparable treatment-related adverse events to the control group.
When was ivonescimab approved in China?
Ivonescimab received approval from the China National Medical Products Administration in May 2024 and was included in the National Reimbursement Drug List in November 2024.
What are the future plans for ivonescimab?
Akeso's partner, Summit Therapeutics, plans to submit a Biologics License Application to the FDA in late 2025, aiming for approval for treating EGFR-positive, TKI-resistant NSCLC.
